Figure 1.

A cell-based phenotypic screening identifies Oxa12 as a necroptosis inhibitor. (A) Schematic overview of the two-step screening workflow. (B) Determination of the ability of the compound to inhibit necroptosis. Cell metabolic activity is depicted as a percentage of the control (DMSO = 0; Nec-1 at 30 µM) for compounds at 30 µM tested in BV2 murine microglia cells exposed to 25 µM zVAD-fmk for 24 h. (C) Half-maximal effective concentration (EC₅₀) determination in BV2 murine microglia cells in a dose-response concentration (0.1 to 50 µM Oxa12) plus 25 µM zVAD-fmk for 24 h. (D) Half-maximal effective concentration (EC₅₀) determination in BV2 murine microglia cells in a dose-response concentration (0.01 to 50 µM Nec-1) plus 25 µM zVAD-fmk for 24 h.